Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
Automated microscopy and Spatial Proteomics
Real-time, label free cell analysis
Nano and micro particle analysis
Accelerate to discover
Related topics
A 19-color single-tube Full Spectrum Flow Cytometry for the detection of Acute Myeloid Leukemia
Mar 13, 2024
This recent publication in Cytometry Part A describes the development and comprehensive workflow of a single-tube,...
18F-labeled somatostatin analogs for somatostatin receptors (SSTRs) targeted PET imaging of NETs
Mar 11, 2024
A novel 18F-radiolabeled somatostatin analogue, [Al18F]NODA-MPAA-HTA, was synthesized and evaluated for positron...
Discover Yokogawa CellVoyager CQ1: Benchtop High-Content Analysis System
Mar 8, 2024
Unlike flow cytometers, the CellVoyager CQ1 confocal quantitative image cytometer does not require pretreatment such as...
Real-time and quantitative analysis of Macrophage Phagocytosis with RTCA eSight
Feb 23, 2024
The eSight is currently the only instrument that interrogates cell health and behavior using cellular
impedance...
Visualization of Tumor-Related Blood Vessels in Small Animals by Photoacoustic 3D Imaging System
Feb 21, 2024
In Vivo Label-Free Observation of Tumor-Related Blood Vessels in Small Animals Using a Newly Designed Photoacoustic 3D...
Therapeutic effects of mesenchymal stem cells in myocardial infarction
Feb 19, 2024
Intrapericardial hydrogel injection generates high cell retention and augments therapeutic effects of mesenchymal stem...
Whole-slide biomarker quantitation in 82-patient NSCLC cohort study of acquired resistance to PD-(L)
Feb 7, 2024
Samples from 82 patients with NSCLC and matched pre- and post-ICI biopsies were subjected to genomic profiling and to...
Evaluation with BLI of synthetic immune checkpoint engagers in allogenic mice
Jan 17, 2024
Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity
Jun 4, 2018
Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.
The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.
Related technologies: Conventional flow cytometry
Brand profile
Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
More info at:
www.aceabio.com